BG108383A - АГОНИ'' НА АД...НОЗИН А2А Р...-...П'ОР И АН'ИХОЛИН...РГИ-НО 'Р...Д''ВО В КОМБИНА-ИЯ ЗА Л...-...НИ... НА ОБ''Р"К'ИВНИ ЗАБОЛЯВАНИЯ НА ДИХА'...ЛНИ'... ПЪ'И(tm)А - Google Patents

АГОНИ'' НА АД...НОЗИН А2А Р...-...П'ОР И АН'ИХОЛИН...РГИ-НО 'Р...Д''ВО В КОМБИНА-ИЯ ЗА Л...-...НИ... НА ОБ''Р"К'ИВНИ ЗАБОЛЯВАНИЯ НА ДИХА'...ЛНИ'... ПЪ'И(tm)А Download PDF

Info

Publication number
BG108383A
BG108383A BG108383A BG10838303A BG108383A BG 108383 A BG108383 A BG 108383A BG 108383 A BG108383 A BG 108383A BG 10838303 A BG10838303 A BG 10838303A BG 108383 A BG108383 A BG 108383A
Authority
BG
Bulgaria
Prior art keywords
amino
alkyl
anticholinergic agent
receptor agonist
selective adenosine
Prior art date
Application number
BG108383A
Other languages
Bulgarian (bg)
English (en)
Inventor
Roisin A. Armstrong
Michael Yeadon
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129275A external-priority patent/GB0129275D0/en
Priority claimed from GB0210238A external-priority patent/GB0210238D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG108383A publication Critical patent/BG108383A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG108383A 2001-05-25 2003-11-24 АГОНИ'' НА АД...НОЗИН А2А Р...-...П'ОР И АН'ИХОЛИН...РГИ-НО 'Р...Д''ВО В КОМБИНА-ИЯ ЗА Л...-...НИ... НА ОБ''Р"К'ИВНИ ЗАБОЛЯВАНИЯ НА ДИХА'...ЛНИ'... ПЪ'И(tm)А BG108383A (bg)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29384201P 2001-05-25 2001-05-25
GB0129275A GB0129275D0 (en) 2001-12-06 2001-12-06 Pharmaceutical combination
GB0210238A GB0210238D0 (en) 2002-05-03 2002-05-03 Pharmaceutical composition
PCT/EP2002/005725 WO2002096462A1 (en) 2001-05-25 2002-05-24 An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases

Publications (1)

Publication Number Publication Date
BG108383A true BG108383A (bg) 2004-08-31

Family

ID=27256345

Family Applications (1)

Application Number Title Priority Date Filing Date
BG108383A BG108383A (bg) 2001-05-25 2003-11-24 АГОНИ'' НА АД...НОЗИН А2А Р...-...П'ОР И АН'ИХОЛИН...РГИ-НО 'Р...Д''ВО В КОМБИНА-ИЯ ЗА Л...-...НИ... НА ОБ''Р"К'ИВНИ ЗАБОЛЯВАНИЯ НА ДИХА'...ЛНИ'... ПЪ'И(tm)А

Country Status (22)

Country Link
US (1) US20040171576A1 (es)
EP (1) EP1395287A1 (es)
KR (1) KR20030097901A (es)
CN (1) CN1535161A (es)
AP (1) AP2003002911A0 (es)
BG (1) BG108383A (es)
BR (1) BR0209986A (es)
CA (1) CA2448086A1 (es)
CO (1) CO5540324A2 (es)
CZ (1) CZ20033126A3 (es)
EE (1) EE200300586A (es)
HU (1) HUP0400029A2 (es)
IL (1) IL158774A0 (es)
MA (1) MA27028A1 (es)
MX (1) MXPA03010787A (es)
NO (1) NO20035202D0 (es)
OA (1) OA12609A (es)
PA (1) PA8546101A1 (es)
PL (1) PL366899A1 (es)
SK (1) SK14302003A3 (es)
SV (1) SV2003001055A (es)
WO (1) WO2002096462A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
NZ556354A (en) 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
EP1778712B1 (en) 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20090286779A1 (en) 2006-09-29 2009-11-19 Novartis Ag Pyrazolopyrimidines as lipid kinase inhibitors
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
BRPI0906838A2 (pt) 2008-01-11 2015-07-14 Novartis Ag Pirimidinas como inibidores de quinase
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
IN2012DN01453A (es) 2009-08-20 2015-06-05 Novartis Ag
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
ES2894830T3 (es) 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
ES2831416T3 (es) 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
CA2347512C (en) * 1998-10-16 2005-12-06 Pfizer Inc. Adenine derivatives
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
NO20035202D0 (no) 2003-11-24
CZ20033126A3 (cs) 2004-09-15
EP1395287A1 (en) 2004-03-10
PL366899A1 (en) 2005-02-07
OA12609A (en) 2006-06-09
BR0209986A (pt) 2004-04-06
WO2002096462A1 (en) 2002-12-05
MXPA03010787A (es) 2004-03-02
KR20030097901A (ko) 2003-12-31
PA8546101A1 (es) 2003-12-10
CN1535161A (zh) 2004-10-06
MA27028A1 (fr) 2004-12-20
HUP0400029A2 (hu) 2004-04-28
AP2003002911A0 (en) 2003-12-31
SV2003001055A (es) 2003-11-14
SK14302003A3 (sk) 2004-08-03
EE200300586A (et) 2004-04-15
IL158774A0 (en) 2004-05-12
CA2448086A1 (en) 2002-12-05
CO5540324A2 (es) 2005-07-29
US20040171576A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
BG108383A (bg) АГОНИ'' НА АД...НОЗИН А2А Р...-...П'ОР И АН'ИХОЛИН...РГИ-НО 'Р...Д''ВО В КОМБИНА-ИЯ ЗА Л...-...НИ... НА ОБ''Р"К'ИВНИ ЗАБОЛЯВАНИЯ НА ДИХА'...ЛНИ'... ПЪ'И(tm)А
US7107985B2 (en) Pharmaceutical combination
US20040147544A1 (en) Pde4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
EP1455799B1 (en) Pharmaceutical combinations of adenosine a-2a and beta-2-adrenergic receptor agonists
US20030109485A1 (en) Pharmaceutical combination
US20040167153A1 (en) Pharmaceutical combination
AU2002316924A1 (en) An adenosine A2A receptor agonist and an anticholiergic agent in combination for treating obstructive airways diseases
AU2002344167A1 (en) A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
ZA200308602B (en) A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases.